WHAT'S KNOWN ON THIS SUBJECT:
Although waning immunity with the childhood pertussis vaccination series has been reported, there are limited data on duration of protection of the adolescent pertussis vaccine (Tdap), especially among those who have received only acellular vaccines.
WHAT THIS STUDY ADDS:
This study reports that protection from Tdap wanes substantially 2 to 4 years after vaccination among adolescents who received all acellular vaccines during childhood. This waning protection is likely contributing to the increase in adolescent pertussis. Despite high childhood and adolescent vaccination coverage, .48 000 pertussis cases were reported in the United States in 2012, the greatest number reported since 1955. 1 In addition, there were new and concerning changes in the age distribution of pertussis cases, with increasing incidence among fully vaccinated children and adolescents within a few years of vaccination. [1] [2] [3] Although infants ,1 year of age continue to have the highest rates of pertussis, increased rates among 7-to 10-year-olds were recently observed. 3 Notably, this cohort of children was among the first to receive solely acellular pertussis vaccines for the childhood series. Waning immunity after vaccination with diphtheria-tetanus-acellular pertussis (DTaP) vaccines appears to be a major contributing factor for increased disease risk. [4] [5] [6] Because tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap) was recommended for adults and adolescents only in 2006, studies estimating Tdap vaccine effectiveness (VE) and duration of protection are few. Several observational studies noted an overall VE range of 64% to 78% within 2 years of vaccination. [7] [8] [9] [10] To our knowledge, only 1 study has measured Tdap duration of protection for .2 years, and it concluded that VE waned over time. 11 In 2012, Washington State declared a pertussis epidemic with nearly 5000 cases reported. An unexpectedly high disease incidence was seen in adolescents 13 to 14 years of age despite Tdap coverage of 86%. 2, 12 The emergence of disease in this age group had not been observed since the introduction of Tdap, raising concerns for waning immunity after the Tdap dose in adolescents who received all acellular pertussis vaccines as children. The epidemic in Washington provided an opportunity to estimate Tdap VE and duration of protection among the first cohort of adolescents who received all acellular vaccines.
METHODS

Study Oversight
This evaluation was conducted as part of the public health response to the 2012 Washington pertussis epidemic and was determined to be nonresearch program evaluation by the Centers for Disease Control and Prevention Human Research Protection Office and the Washington State Department of Social and Health Services Institutional Review Board.
Study Design and Population
To estimate Tdap VE and duration of protection, we conducted a matched case-control study. 14 We selected 3 controls for each case, matched by birth year and primary provider clinic. Controls were randomly selected from a clinicgenerated patient roster that included all adolescents born in the same year as the case and who had at least 1 clinic visit since 2005. Potential controls were excluded and replaced with another randomly selected control if the provider suspected or diagnosed pertussis during the study period, the patient had been discharged from the clinic, the patient had an out-of-state home zip code, or patient medical records were unavailable. The symptom onset date of the case was used as the enrollment date for each case and associated matched controls.
Demographic information (date of birth, gender, home zip code, ethnicity, race) and vaccination histories for cases and controls were collected at provider clinics by using a standardized protocol and medical chart abstraction form. Vaccination date, product, manufacturer, and lot number were recorded for all documented pertussis-, diphtheria-, or tetanus-containing vaccines, including the childhood series and adolescent dose when available. To verify brand, we matched available lot numbers for the childhood series and adolescent dose with known lot numbers provided by the Washington State Department of Health and 2 pertussis vaccine manufacturers (GlaxoSmithKline, Brentford, United Kingdom; Sanofi Pasteur, Swiftwater, PA).
We supplemented provider vaccination histories with information from the Washington State Immunization Information System. 15 If vaccination history was available in both sources but discrepant, provider records were used as the definitive source. If Tdap vaccination status remained unknown after reviewing these sources, parents or guardians were contacted to verify Tdap vaccine receipt.
The childhood series was considered complete and on schedule if the participant had documentation in the provider records or immunization registry of 5 doses of diphtheriatetanus toxoids-pertussis (DTP) or DTaP meeting the following criteria: doses 1 through 3 before the first birthday, dose 4 on or after the first birthday and before the second birthday, and dose 5 on or after the fourth birthday and before the seventh birthday. 16 We classified participants as vaccinated if a Tdap vaccination date was confirmed in the provider records, the immunization registry, or by parent interview. We classified participants as unvaccinated if no record of Tdap vaccination date was found in the provider records or the immunization registry and Tdap nonreceipt was confirmed by a parent. In addition, participants were classified as unvaccinated if Tdap receipt was confirmed but the vaccination occurred after the enrollment date or if Tdap was received within 2 weeks before the enrollment date. We considered a participant's vaccination status to be unknown if a Tdap vaccination date was not documented in the provider records or the immunization registry and the parent interview was inconclusive.
The Washington State Childhood Vaccination Program has been the sole distributor of childhood and adolescent vaccines to public and private health care providers since the early 1990s. 17, 18 We reviewed available vaccine distribution data and determined that the transition of whole-cell to acellular pertussis vaccines for the complete childhood series occurred during 1997, after which we assumed that whole-cell vaccines were no longer available. We verified this assumption by crosschecking study-obtained lot numbers against manufacturer data.
To evaluate the impact of the wholecell or acellular pertussis childhood vaccination series on Tdap VE, study participants were stratified on the basis of birth year into 2 groups. The acellular group included adolescents born from 1998 to 2000 and were assumed to have received all acellular pertussis vaccines for the childhood series, whereas the mixed group included those born from 1993 to 1997 and were assumed to have received a mix of whole-cell and acellular pertussis vaccines.
Statistical Analysis
To estimate the association between pertussis and Tdap receipt, we used conditional logistic regression to calculate odds ratios, accounting for matching factors (provider and birth year). VE was calculated as: 1 2 odds ratio 3 100%. Tdap-unvaccinated participants were the reference group in all models. We estimated duration of protection by measuring the association between pertussis and time since Tdap vaccination (,12 months, 12-23 months, 24-47 months).
We excluded cases and controls if Tdap vaccination status was unknown, or if there was documentation of inadvertent administration of DTaP during adolescence, Tdap before the age of 10 years, or $2 Tdap doses. In addition, controls were excluded if they had ever been reported to the Washington State Department of Health as having pertussis.
The primary analysis measured Tdap VE and duration of protection in study participants who received all acellular pertussis vaccines for the childhood series (birth years 1998-2000; ages 11-14 years).
Additional subgroup analyses assessed the stability of the VE estimates by restricting the analysis to those with confirmed and probable case status, those with confirmed case status only, or those with a complete and on-schedule childhood series. We also evaluated Tdap VE among participants who received a mix of whole-cell and acellular vaccines (birth years 1993-1997; ages 15-19 years), as well as differences in VE by Tdap product.
Statistical comparison of demographic characteristics between cases and controls was performed by using conditional logistic regression. We evaluated trends in Tdap vaccine status by birth year using the Cochran-Armitage test. All analyses were conducted in SAS software, version 9.3 (SAS Institute, Cary, NC).
RESULTS
During the study period, 1153 pertussis cases among adolescents were reported in Washington. Of those, 959 were reported in the 7 participating counties, representing 83% of all Washington adolescent cases and 73% of all Washington providers reporting adolescent cases. Pertussis incidence for this age group was 182.3 per 100 000 persons during the study period.
Data were collected for 887 cases and 2599 matched controls. Data were not collected for 72 cases for the following reasons: a provider was not available for the patient (n = 45; 63.4%), the provider refused to participate (n = 14; 19.7%), or the provider was located outside the participating counties (n = 12; 16.9%). An additional 51 cases (5.8%) and 277 controls (10.7%) were excluded from the analysis ( Table 1 ). The final analysis included 836 cases and 2322 controls. Of the 836 cases, 656 (78.5%) were classified as confirmed, 92 (11.0%) as probable, and 88 (10.5%) as suspect. Table 2 lists demographic and vaccine characteristics of the cases and controls included in the analysis. The median age among study participants was 14 years; 54% were born between 1998 and 2000. Cases were more likely to be white (P = .003) and non-Hispanic (P = .03) than controls; however, a substantial amount of race and ethnicity data was not documented in the medical records and therefore was unknown. Although 74% of cases and 75% of controls had 5 documented doses for the childhood series, only 60% of cases and 58% of controls had a 5-dose series that was on schedule. Brand was identified by lot number for 25% to 29% of the childhood doses administered, depending on the dose number. Although documentation of childhood series lot numbers was limited, all childhood vaccines administered in study participants during 1998 or later with available lot numbers were confirmed to be acellular pertussis vaccines.
Eighty-one percent of cases and 90% of controls were vaccinated with Tdap, and both had similar ages at vaccination and time since vaccination. Overall, .84% of study participants were vaccinated with Tdap at the recommended ages of 11 to 12 years. Tables  5 and 6 ). Similarly, a subgroup analysis excluding those with suspect case status was not notably different from the primary analysis (data not shown).
The overall Tdap VE for the mixedvaccine group (386 cases, 1076 controls) was 51.5% (95% CI: 26.1% to 68.1%). Because the mixed group was heavily weighted toward participants who received Tdap at least 3 years before study enrollment (Fig 2) , Tdap duration of protection was stratified by less or more than 4 years since vaccination. The VE estimates for each of these time points were similar to the overall VE Data are presented as n (%). a Only controls were verified as to whether they had been reported as a pertussis case previously. a Cases and controls were matched on birth year, and therefore no P value was calculated. b A complete and on-schedule primary series is considered the following: doses 1 through 3 before the first birthday, dose 4 on or after the first birthday and before the second birthday, and dose 5 on or after the fourth birthday and before the seventh birthday. c P values do not apply to unknown data.
estimate, with overlapping CIs (,48 months: 51.5%; 95% CI: 24.3% to 69%; 48-84 months: 52.2%; 95% CI: 24.6% to 69.6%). Direct comparisons between the mixed group and acellular group could not be made for the following reasons: significant differences in the median age and time since vaccination between the groups (P , .0001), a greater proportion of participants with unknown Tdap vaccination status in the mixed group compared with the acellular group (7.2% vs 4.5%, respectively; P = .0007), and a significant trend of increasing unknown Tdap vaccination status with increasing age (CochranArmitage trend test, z = 26.04, P , .0001).
The Tdap product (Boostrix; GlaxoSmithKline; Adacel; Sanofi Pasteur) was verified by lot number in 76% of recipients (Table 2) . Cases were more likely to have been vaccinated with Adacel compared with controls (P = .05), despite Adacel being used less frequently than Boostrix (17% vs 59%, respectively). Analyses of VE estimates by product were stratified by vaccine group. Regardless of group analyzed, Boostrix had slightly higher effectiveness than Adacel, although CIs overlapped (Table 4) . Productspecific VE estimates in the mixed group were slightly lower than in the acellular group, but CIs again overlapped.
DISCUSSION
Tdap was recommended in the early 2000s to address the burden of pertussis among adolescents and adults. 19 The preferred administration age of 11 to 12 years targeted the peak of disease in adolescence and supported the established adolescent vaccination platform. Among adolescents, national Tdap vaccine uptake has increased steadily after its introduction, and early evaluations indicated it was effective in reducing the adolescent disease burden. [20] [21] [22] However, it is notable that the group of adolescents who initially received Tdap also received whole-cell vaccines during childhood. Despite promising indicators, the number of pertussis cases among adolescents has climbed during 2012, mainly in 13-to 14-year-olds who received solely acellular vaccines. 1 We have found that among adolescent recipients of all acellular vaccines, overall Tdap VE is 64%, with substantial waning of protection after 2 years. Although the study methodology differed substantially, our results were consistent with a recent Tdap VE study in Wisconsin. 11 The waning protection revealed in both studies indicates that it likely is a major contributor to the increasing pertussis incidence in this age group.
Although an initial study aim was to compare Tdap VE between adolescents who received a mix of whole-cell and acellular vaccines with those who received all acellular . A complete and on-schedule primary series is considered the following: doses 1 through 3 before the first birthday, dose 4 on or after the first birthday and before the second birthday, and dose 5 on or after the fourth birthday and before the seventh birthday. Refer to Table 3 and Supplemental Tables 5 and  6 for CIs for each of these time points. vaccines, this was not possible due to the difference in time since vaccination between the groups. Seventy-seven percent of adolescents in the mixed-vaccine group received Tdap at least 3 years before study enrollment in comparison with only 4% in the acellular vaccine group. Of note, however, was the finding that VE estimates in the mixed-vaccine group at less or more than 4 years since Tdap vaccination were similar (51.5% vs 52.2%). This finding suggests that durability of protection after Tdap is limited regardless of type of vaccines received during childhood, but that the rate of waning may be higher in those vaccinated solely with acellular vaccines.
Reasons for more rapid waning of Tdap-induced protection in persons vaccinated with acellular pertussis vaccines may be related to the immunologic response to acellular vaccines and a potential limitation of acellular vaccines to prevent transmission. Both whole-cell and acellular vaccines elicit pertussisspecific antibodies, which decrease after immunization. 23, 24 However, other immunologic mechanisms, such as cell-mediated immunity, have also been associated with protection against pertussis disease and may be suboptimal after vaccination with acellular vaccines. [25] [26] [27] [28] In addition, recent data from a novel nonhuman primate model showed that although acellular vaccines prevented symptomatic disease, they failed to prevent infection and transmission. 29 Recently observed genetic variation in pertussis strains may also be playing a role in VE. In particular, the rapid emergence of pertactindeficient pertussis strains is concerning, because pertactin is one of the major antigenic components of acellular pertussis vaccines. 30, 31 A recent evaluation of available isolates obtained during the Washington 2012 outbreak revealed that over half carried a particular mutation resulting in pertactin deficiency. 30 Because our study was not designed to measure VE against these emerging strains, further evaluation is needed.
Analysis of Tdap product revealed a trend toward slightly higher VE estimates with Boostrix as opposed to Adacel, regardless of vaccine group analyzed. However, CIs overlapped between Tdap product and between vaccine group. On the basis of this analysis, definitive conclusions cannot be drawn regarding specific Tdap product effectiveness; nevertheless, these trends mirror findings of the Wisconsin study, which showed higher VE with Boostrix. 11 As with all case-control studies, unaddressed biases could influence our findings. The likelihood and timing of Tdap receipt are strongly correlated with age; to control for this potential bias, we matched on birth year. We also matched on primary provider clinic in an attempt to control for differences in provider TIMING IS KEY: During the college football season, some games begin at noon while others begin late in the evening. I have always wondered if the start time for the game could affect athletic performance. I have noticed that when I exercise I seem slower first thing in the morning. As it turns out, athletes have a natural circadian rhythm and performance depends on whether the event is in sync with the athlete's circadian rhythm.
As reported in The New York Times (Well: January 29, 2015), researchers evaluated the athletic performance of 20 competitive field hockey players and 22 competitive squash players six times a day. When the results were assessed in aggregate, the researchers found that overall, athletic performance peaked in the evening. This was consistent with previous findings by other researchers. However, when they looked at peak performance based on time of day and whether the athlete was an early morning, mid-morning, or late morning riser, they found that athletic performance peaked 4 to 6 hours after waking. Early morning risers did their best at noon, while late risers did their best in the evening. Nobody did well early in the morning. In fact, performance diminished by as much as 26% if not in sync with the natural circadian rhythm. While the study involved a limited number of adults, and the exercise measured was not related to the sporting event, the data suggest that to maximize performance athletes should consider the time of the event. If necessary, they should stagger their sleep time to help ensure their circadian rhythm is in sync with the timing of the event.
As for me, I do not think it matters too much what time of day I exercise. After all, I am not in a competition. Still, it is nice to know there is a reason why I seem so sluggish while exercising early in the morning.
Noted by WVR, MD
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